DCZ3301
Based on 1 Customer Validation
DCZ3301 is an apoptosis inducer. DCZ3301 modulates JAK2/STAT3, ERK1/2, and PI3K/AKT pathways. DCZ3301 induces G2/M and M phase cell cycle arrest and inhibits cell proliferation and viability. DCZ3301 enhances DNA damage, inhibits DNA repair, and suppresses angiogenesis. DCZ3301 can be used for the research of diffuse large B-cell lymphoma, multiple myeloma and leukemia/lymphoma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.73%
- CAS No.: 2136278-38-9
- 화학식: C20H16ClF3N6O2
- 분자량:464.83
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
제품 설명
IC50 & Target
[1]|
JAK2 |
p-STAT3 |
ERK1 |
ERK2 |
In Vitro
DCZ3301 (1-32 μM; 48 h) potently inhibits proliferation of OCI-LY8, NU-DUL-1, SUDHL-4, DB, and TMD8 DLBCL cell lines[1].
DCZ3301 (1-32 μM; 24-72 h) inhibits proliferation of OCI-LY8 and NU-DUL-1 DLBCL cell lines in a time-dependent manner[1].
DCZ3301 (2-20 μM; 48 h) inhibits proliferation of OCI-LY8 and NU-DUL-1 DLBCL cell lines in the presence of IL-6 or IGF-1, with its growth-inhibitory effect unaffected by these protumorigenic cytokines[1].
DCZ3301 (4-20 μM; 24-72 h) induces dose- and time-dependent apoptosis in OCI-LY8 and NU-DUL-1 DLBCL cell lines[1].
DCZ3301 (8-16 μM; 48 h) induces apoptosis in OCI-LY8 and NU-DUL-1 DLBCL cell lines via both extrinsic and intrinsic caspase-dependent pathways[1].
DCZ3301 (4 μM; 8-24 h) induces time-dependent G2/M phase cell cycle arrest in OCI-LY8 and NU-DUL-1 DLBCL cell lines when treated with 4 μM for 8, 12, or 24 h[1].
DCZ3301 (4-8 μM; 24 h) modulates cell cycle-related proteins (upregulating p-CHK2 and p21, downregulating cdc25A, cdc25C, and cyclinB1) in OCI-LY8 and NU-DUL-1 DLBCL cell lines[1].
DCZ3301 (8-16 μM; 48 h) regulates the Akt, ERK1/2, and JAK2/STAT3 signaling pathways[1].
DCZ3301 (4-8 μM; 48 h) has its antiproliferative effect enhanced in STAT3-knockdown OCI-LY8 and NU-DUL-1 DLBCL cell lines[1].
DCZ3301 (8-16 μM; 12-48 h) inhibits Lyn phosphorylation (Y507) in a dose- and time-dependent manner, with a corresponding decrease in STAT3 phosphorylation, in OCI-LY8 and NU-DUL-1 DLBCL cell lines[1].
DC50Z3301 (8-16 μM; 48 h) modulates DNA repair-related protein expression in NCI-H929R and RPMI-8226R5 BTZ-resistant multiple myeloma cells after 48 hours of treatment[2].
DCZ3301 (8 μM; 48 h) upregulates γ-H2A.X expression and induces γ-H2A.X foci formation in NCI-H929R and RPMI-8226R5 BTZ-resistant multiple myeloma cells, confirming enhanced DNA damage[2].
DCZ3301 (5 μM; 24 h) suppresses the migration of human umbilical vein endothelial cells (HUVECs) in a wound healing assay[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:OCI-LY8, NU-DUL-1, SUDHL-4, DB, TMD8 (diffuse large B-cell lymphoma cell lines)
-
Concentration:1 μM; 2 μM; 4 μM; 8 μM; 16 μM; 32 μM
-
Incubation Time:48 h
-
Result:Caused a dose-dependent decrease in DLBCL cell proliferation.
Achieved IC50 values of 7.1 μM (OCI-LY8), 9.7 μM (NU-DUL-1), 6.67 μM (SUDHL-4), 8.04 μM (DB), and 9.66 μM (TMD8).
-
Cell Line:OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
-
Concentration:1 μM; 2 μM; 4 μM; 8 μM; 16 μM; 32 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Inhibited proliferation of OCI-LY8 and NU-DUL-1 cells in a time-dependent manner, with greater inhibition observed at longer incubation times.
-
Cell Line:OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
-
Concentration:2 μM; 4 μM; 6 μM; 8 μM; 10 μM; 12 μM; 16 μM; 20 μM
-
Incubation Time:48 h
-
Result:Induced growth inhibition that was not altered by the presence of IL-6 or IGF-1, despite these cytokines alone stimulating DLBCL cell growth.
-
Cell Line:OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
-
Concentration:4 μM; 5 μM; 8 μM; 10 μM; 12 μM; 15 μM; 16 μM; 20 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Induced apoptosis in OCI-LY8 and NU-DUL-1 cells in a dose- and time-dependent manner.
Increased apoptosis rates with higher concentrations and longer incubation times, with statistically significant increases compared to controls.
-
Cell Line:OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
-
Concentration:8 μM; 16 μM
-
Incubation Time:48 h
-
Result:Caused a dose-dependent increase in cleaved caspase-3, caspase-8, caspase-9, and PARP, while downregulating Bcl-2 and Bcl-xL and upregulating Bax.
Suppressed apoptosis in NU-DUL-1 cells when pre-incubated with pan-caspase inhibitor Z-VAD-FMK.
-
Cell Line:OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
-
Concentration:4 μM
-
Incubation Time:8 h; 12 h; 24 h
-
Result:Caused a time-dependent accumulation of cells in the G2/M phase in both OCI-LY8 and NU-DUL-1 cell lines, with statistically significant increases (P < 0.05, P < 0.001) compared to controls at 12 and 24 h.
-
Cell Line:OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
-
Concentration:4 μM; 8 μM
-
Incubation Time:24 h
-
Result:Increased p-CHK2 and p21 protein expression, while decreasing protein levels of cdc25A, cdc25C, and cyclinB1 in both OCI-LY8 and NU-DUL-1 cells.
-
Cell Line:OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
-
Concentration:8 μM; 16 μM
-
Incubation Time:48 h
-
Result:Upregulated phosphorylated ERK1/2, downregulated phosphorylated Akt, phosphorylated JAK2, and phosphorylated STAT3, and reduced c-Myc expression in a dose-dependent manner in both OCI-LY8 and NU-DUL-1 cells.
-
Cell Line:OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines, STAT3 knockdown)
-
Concentration:4, 8 μM
-
Incubation Time:48 h
-
Result:Enhanced antiproliferative efficacy in STAT3-knockdown OCI-LY8 and NU-DUL-1 cells compared to negative control siRNA-transfected cells, with statistically significant differences (P < 0.05) observed at both concentrations.
-
Cell Line:OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
-
Concentration:8 μM; 16 μM
-
Incubation Time:12 h; 24 h; 36 h; 48 h
-
Result:Downregulated phosphorylated Lyn (Y507) in a dose- and time-dependent manner, while having no effect on phosphorylated Syk.
Decreased phosphorylated Lyn correlated with a synchronous decrease in phosphorylated STAT3.
-
Cell Line:OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines, Lyn-overexpressing)
-
Concentration:16 μM
-
Incubation Time:24 h
-
Result:Caused a greater suppression of phosphorylated STAT3 in Lyn-overexpressing cells compared to control cells after 24 h, despite Lyn-overexpressing cells exhibiting higher levels of phosphorylated STAT3 than control cells without treatment.
-
Cell Line:BTZ-resistant multiple myeloma cell lines NCI-H929R and RPMI-8226R5
-
Concentration:8 μM
-
Incubation Time:48 h
-
Result:Increased γ-H2A.X expression and formation of γ-H2A.X foci, indicating increased DNA double-strand breaks.\nInduced the formation of multipolar mitotic spindles, a hallmark of mitotic catastrophe.
In Vivo
DCZ3301 (50 mg/kg; i.p.; 2 consecutive days followed by 1 day of vehicle; for 20 days) significantly inhibits tumor growth in a BTZ-resistant multiple myeloma xenograft model, reduces tumor cell proliferation[2].
DCZ3301 (50 mg/kg; i.p.; daily; 14 days) does not induce significant acute liver or kidney toxicity in healthy BALB/C nude mice[2].
DCZ3301 (30 mg/kg; i.p.; daily; 14 days) significantly inhibits T-cell leukemia/lymphoma xenograft tumor growth in BALB/c nude mice[3].
Treatment with DCZ3301 (30 mg/kg; i.p.; daily; 14 days) significantly inhibits tumor growth and reduces tumor weight in a Jurkat cell xenograft model of T-cell leukemia[4].
DCZ3301 (50-200 μM; topical eye drops; three times daily; 7 days) significantly reduces corneal neovascularization area and attenuates corneal stroma edema in alkali-burned mice, with 200 μM producing a larger reduction in CNV area compared to vehicle control[5].
DCZ3301 (200 μM; topical eye drops; three times daily; 7 days) does not significantly affect corneal epithelial thickness or endothelial cell density in healthy BALB/c mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (6-week-old male, athymic, nu/nu, subcutaneous xenograft model)[1]
-
Dosage:40 mg/kg
-
Administration:i.p.; daily; 12 days
-
Result:Reduced tumor volume significantly compared to controls by day 12 (P < 0.05).
Showed no significant difference in mouse body weight compared to controls.
Increased cell necrosis in tumor tissues via H&E staining.
Increased apoptotic cells in tumor tissues via TUNEL staining.
Downregulated phosphorylated STAT3 expression in tumor tissues via immunohistochemistry.
Showed no evidence of organ dysfunction or growth disorder in functional organs.
-
Animal Model:BALB/C nude mice (weight monitored during study)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; 2 consecutive days followed by 1 day of vehicle; for 20 days
-
Result:Significantly reduced tumor volume compared to control group on day 20.
Did not cause changes in mouse body weight or significant differences in serum levels of ALT, AST, Cr, or BUN.
Increased tumor cell shrinkage and fragmentation relative to controls.
Reduced Ki-67 expression in tumor tissue.
Increased cleaved-caspase 3 expression in tumor tissue.
Upregulated γ-H2A.X, phospho-ATM, and phospho-CHK1 expression in tumor tissue.
Increased percentage of TUNEL-positive cells in tumors.
-
Animal Model:BALB/C nude mice (weight monitored during study)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; daily; 14 days
-
Result:Showed no significant differences in serum levels of ALT, AST, Cr, or BUN compared to vehicle-treated controls.
-
Animal Model:BALB/c nude (5-week-old male, subcutaneous xenograft with Jurkat cells)[3]
-
Dosage:30 mg/kg
-
Administration:i.p.; daily; 14 days
-
Result:Reduced final tumor volumes to statistically significant levels (P < 0.01).
Reduced final tumor weights to statistically significant levels (P < 0.001).
Caused no significant change in mouse body weight compared to vehicle controls.
-
Animal Model:BALB/c nude (5-week-old male, subcutaneous xenograft model)[4]
-
Dosage:30 mg/kg
-
Administration:i.p.; daily; 14 days
-
Result:Reduced tumor volume by a statistically significant margin on days 12 and 14 of treatment (P < 0.01).
Lowered final tumor weight significantly compared to controls (P < 0.001).
Caused no significant change in mouse body weight compared to vehicle-treated groups.
-
Animal Model:BALB/c (6-8 week old male, alkali-burn induced corneal neovascularization)[5]
-
Dosage:50 μM; 200 μM
-
Administration:topical eye drops; three times daily; 7 days
-
Result:Significantly reduced the ratio of corneal neovascularization (CNV) area compared to vehicle control (P < 0.01).
Significantly reduced the ratio of CNV area compared to vehicle control (P < 0.0001).
Greatly reduced corneal stroma thickness compared to vehicle control (P < 0.001).
Greatly reduced corneal stroma thickness compared to vehicle control (P < 0.0001).
-
Animal Model:BALB/c[5]
-
Dosage:200 μM
-
Administration:topical eye drops; three times daily; 7 days
-
Result:Did not cause a significant difference in central corneal epithelial thickness compared to saline-treated controls (P > 0.05).
Did not cause a significant difference in corneal endothelial cell density compared to saline-treated controls (P > 0.05).
Maintained regular shape of corneal endothelial cells.
Chemical Information
-
CAS No. 2136278-38-9
-
Appearance Solid
-
분자량 464.83
-
화학식 C20H16ClF3N6O2
-
Color White to off-white
-
SMILES
O=C(C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=N)N=C2)=C1)NC
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
In Vitro:
DMSO : 50 mg/mL (107.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
순도&문서
-
Data Sheet (297 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sun X, et al. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway. Cell Death Dis. 2017;8(10):e3111. Published 2017 Oct 12. [Content Brief]
[2]. Hu L, et al. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe. J Exp Clin Cancer Res. 2020;39(1):105. Published 2020 Jun 9. [Content Brief]
[3]. Xiao W, et al. DCZ3301, a novel aryl-guanidino inhibitor, induces cell apoptosis and cell cycle arrest via suppressing the PI3K/AKT pathway in T-cell leukemia/lymphoma. Acta Biochim Biophys Sin (Shanghai). 2018;50(7):643-650. [Content Brief]
[4]. Xu K, et al. DCZ3301, an aryl-guanidino agent, inhibits ocular neovascularization via PI3K/AKT and ERK1/2 signaling pathways. Exp Eye Res. 2020;201:108267. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1513 mL | 10.7566 mL | 21.5132 mL | 53.7831 mL |
| 5 mM | 0.4303 mL | 2.1513 mL | 4.3026 mL | 10.7566 mL | |
| 10 mM | 0.2151 mL | 1.0757 mL | 2.1513 mL | 5.3783 mL | |
| 15 mM | 0.1434 mL | 0.7171 mL | 1.4342 mL | 3.5855 mL | |
| 20 mM | 0.1076 mL | 0.5378 mL | 1.0757 mL | 2.6892 mL | |
| 25 mM | 0.0861 mL | 0.4303 mL | 0.8605 mL | 2.1513 mL | |
| 30 mM | 0.0717 mL | 0.3586 mL | 0.7171 mL | 1.7928 mL | |
| 40 mM | 0.0538 mL | 0.2689 mL | 0.5378 mL | 1.3446 mL | |
| 50 mM | 0.0430 mL | 0.2151 mL | 0.4303 mL | 1.0757 mL | |
| 60 mM | 0.0359 mL | 0.1793 mL | 0.3586 mL | 0.8964 mL | |
| 80 mM | 0.0269 mL | 0.1345 mL | 0.2689 mL | 0.6723 mL | |
| 100 mM | 0.0215 mL | 0.1076 mL | 0.2151 mL | 0.5378 mL |
Keywords
- DCZ3301
- 2136278-38-9
- DCZ 3301
- DCZ-3301
- Apoptosis
- JAK
- STAT
- ERK
- PI3K
- Akt
- Jurkat T-cell leukemia cells
- T-cell leukemia/lymphoma
- human umbilical vein endothelial cells
- bortezomib-resistant multiple myeloma
- OCI-LY8
- ocular neovascularization
- diffuse large B-cell lymphoma
- NU-DUL-1
- NCI-H929R
- RPMI-8226R5
- Inhibitor
- inhibitor
- inhibit